NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025

Peter L Greenberg; Richard M Stone; Yasmin Abaza; Aref Al-Kali; Sarah Anand; Brian Ball; John M Bennett; Uma Borate; Andrew M Brunner; Wanxing Chai-Ho; Peter Curtin; Amy E DeZern; Karin Gaensler; Zhubin Gahvari; Guillermo Garcia-Manero; Elizabeth A Griffiths; Tamanna Haque; Meagan Jacoby; Brian A Jonas; Sioban Keel; Rashmi Khanal; Ashwin Kishtagari; Yazan Madanat; Lori J Maness; Shannon R McCurdy; Christine McMahon; Olatoyosi Odenike; Afaf Osman; Vishnu V Reddy; David A Sallman; Hamid Sayar; Rory Shallis; Abhay Singh; Tiffany Tanaka; Swapna Thota; Emily Kovach; Jamie Nguyen; Cindy Hochstetler

doi:10.6004/jnccn.2025.0013

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025

Peter L Greenberg, Richard M Stone, Yasmin Abaza, Aref Al-Kali, Sarah Anand, Brian Ball, John M Bennett, Uma Borate, Andrew M Brunner, Wanxing Chai-Ho, Peter Curtin, Amy E DeZern, Karin Gaensler, Zhubin Gahvari, Guillermo Garcia-Manero, Elizabeth A Griffiths, Tamanna Haque, Meagan Jacoby, Brian A Jonas, Sioban KeelRashmi Khanal, Ashwin Kishtagari, Yazan Madanat, Lori J Maness, Shannon R McCurdy, Christine McMahon, Olatoyosi Odenike, Afaf Osman, Vishnu V Reddy, David A Sallman, Hamid Sayar, Rory Shallis, Abhay Singh, Tiffany Tanaka, Swapna Thota, Emily Kovach, Jamie Nguyen, Cindy Hochstetler

Bone Marrow Transplant

Research output: Contribution to journal › Article › peer-review

Abstract

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.

Original language	English
Pages (from-to)	66-75
Number of pages	10
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	23
Issue number	3
DOIs	https://doi.org/10.6004/jnccn.2025.0013
State	Published - Mar 2025

Keywords

Myelodysplastic Syndromes/diagnosis
Humans
Prognosis
Disease Management

Access to Document

10.6004/jnccn.2025.0013

Cite this

Greenberg, P. L., Stone, R. M., Abaza, Y., Al-Kali, A., Anand, S., Ball, B., Bennett, J. M., Borate, U., Brunner, A. M., Chai-Ho, W., Curtin, P., DeZern, A. E., Gaensler, K., Gahvari, Z., Garcia-Manero, G., Griffiths, E. A., Haque, T., Jacoby, M., Jonas, B. A., ... Hochstetler, C. (2025). NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. Journal of the National Comprehensive Cancer Network : JNCCN, 23(3), 66-75. https://doi.org/10.6004/jnccn.2025.0013

@article{25a493f994db4aafb734e0adfcf208c6,

title = "NCCN Guidelines{\textregistered} Insights: Myelodysplastic Syndromes, Version 2.2025",

abstract = "The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.",

keywords = "Myelodysplastic Syndromes/diagnosis, Humans, Prognosis, Disease Management",

author = "Greenberg, {Peter L} and Stone, {Richard M} and Yasmin Abaza and Aref Al-Kali and Sarah Anand and Brian Ball and Bennett, {John M} and Uma Borate and Brunner, {Andrew M} and Wanxing Chai-Ho and Peter Curtin and DeZern, {Amy E} and Karin Gaensler and Zhubin Gahvari and Guillermo Garcia-Manero and Griffiths, {Elizabeth A} and Tamanna Haque and Meagan Jacoby and Jonas, {Brian A} and Sioban Keel and Rashmi Khanal and Ashwin Kishtagari and Yazan Madanat and Maness, {Lori J} and McCurdy, {Shannon R} and Christine McMahon and Olatoyosi Odenike and Afaf Osman and Reddy, {Vishnu V} and Sallman, {David A} and Hamid Sayar and Rory Shallis and Abhay Singh and Tiffany Tanaka and Swapna Thota and Emily Kovach and Jamie Nguyen and Cindy Hochstetler",

year = "2025",

month = mar,

doi = "10.6004/jnccn.2025.0013",

language = "English",

volume = "23",

pages = "66--75",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Harborside Press",

number = "3",

}

Greenberg, PL, Stone, RM, Abaza, Y, Al-Kali, A, Anand, S, Ball, B, Bennett, JM, Borate, U, Brunner, AM, Chai-Ho, W, Curtin, P, DeZern, AE, Gaensler, K, Gahvari, Z, Garcia-Manero, G, Griffiths, EA, Haque, T, Jacoby, M, Jonas, BA, Keel, S, Khanal, R, Kishtagari, A, Madanat, Y, Maness, LJ, McCurdy, SR, McMahon, C, Odenike, O, Osman, A, Reddy, VV, Sallman, DA, Sayar, H, Shallis, R, Singh, A, Tanaka, T, Thota, S, Kovach, E, Nguyen, J & Hochstetler, C 2025, 'NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 23, no. 3, pp. 66-75. https://doi.org/10.6004/jnccn.2025.0013

TY - JOUR

T1 - NCCN Guidelines® Insights

T2 - Myelodysplastic Syndromes, Version 2.2025

AU - Greenberg, Peter L

AU - Stone, Richard M

AU - Abaza, Yasmin

AU - Al-Kali, Aref

AU - Anand, Sarah

AU - Ball, Brian

AU - Bennett, John M

AU - Borate, Uma

AU - Brunner, Andrew M

AU - Chai-Ho, Wanxing

AU - Curtin, Peter

AU - DeZern, Amy E

AU - Gaensler, Karin

AU - Gahvari, Zhubin

AU - Garcia-Manero, Guillermo

AU - Griffiths, Elizabeth A

AU - Haque, Tamanna

AU - Jacoby, Meagan

AU - Jonas, Brian A

AU - Keel, Sioban

AU - Khanal, Rashmi

AU - Kishtagari, Ashwin

AU - Madanat, Yazan

AU - Maness, Lori J

AU - McCurdy, Shannon R

AU - McMahon, Christine

AU - Odenike, Olatoyosi

AU - Osman, Afaf

AU - Reddy, Vishnu V

AU - Sallman, David A

AU - Sayar, Hamid

AU - Shallis, Rory

AU - Singh, Abhay

AU - Tanaka, Tiffany

AU - Thota, Swapna

AU - Kovach, Emily

AU - Nguyen, Jamie

AU - Hochstetler, Cindy

PY - 2025/3

Y1 - 2025/3

N2 - The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.

AB - The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.

KW - Myelodysplastic Syndromes/diagnosis

KW - Humans

KW - Prognosis

KW - Disease Management

UR - http://www.scopus.com/inward/record.url?scp=105000358788&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2025.0013

DO - 10.6004/jnccn.2025.0013

M3 - Article

C2 - 40073835

SN - 1540-1405

VL - 23

SP - 66

EP - 75

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 3

ER -

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this